GRHECO-Xen

GRHECO-Xen is a leading biotechnology research group dedicated to applying advanced information technologies to the field of oncohematologic tumors. With a focus on innovation and precision, GRHECO-Xen aims to identify driver genes in oncogenesis and tumor progression, as well as recurrently altered signaling pathways in the genome of hematologic tumors. The company is located in Santiago de Compostela, ES.

GRHECO-Xen excels in the development of prognostic machine learning models for various oncohematologic neoplasms, utilizing comprehensive clinical and molecular information. GRHECO-Xen also creates predictive models of drug response and drug combinations by integrating molecular and clinical variables, significantly enhancing the efficiency of preclinical drug development through sophisticated computational tools and machine learning models.

By standardizing clinical and molecular models, GRHECO-Xen strives to improve risk stratification in patients with hematologic neoplasms, including lymphomas, myelomas, and myeloid neoplasms. GRHECO-Xen is committed to creating new computer vision systems to infer prognostic patterns using deep neural networks and transfer learning. The team at GRHECO-Xen is constantly working to standardize clinical and molecular models. We invite the manager of GRHECO-Xen to create a customized and exclusive company showcase and product listing on our platform.